Preliminary evidence also suggests that tracking the emergence and decline in rat sarcoma virus oncogene (RAS) mutated clones driving resistance in metastatic colorectal cancer patients treated with anti-EGFR antibodies may guide the timing of anti-EGFR rechallenge [28,29]. This evidence concerns the gene EGFR and metastatic colorectal cancer.